Mar 31, 2021 8:00am EDT Algernon Pharmaceuticals Announces Topline Data From its Phase 2b/3 COVID-19 Trial of Ifenprodil
Mar 29, 2021 7:02am EDT Algernon Pharmaceuticals Announces its Addition to the Market's First Psychedelic Stock Index ETF
Mar 17, 2021 7:00am EDT Algernon Pharmaceuticals Submits U.S. FDA Pre-IND Meeting Request for Psychedelic Drug DMT Clinical Research Program for Stroke
Mar 11, 2021 7:41am EST Algernon Pharmaceuticals Provides Update on Timing of Topline Results for Phase 2b/3 COVID-19 Trial of Ifenprodil
Mar 03, 2021 8:00am EST Algernon Pharmaceuticals CEO and Dr. David Nutt to Discuss DMT Stroke Clinical Research Program Featured on BioPub Webcast Hosted by Dr. KSS MD, PhD
Mar 01, 2021 8:00am EST Algernon Pharmaceuticals to Conduct Phase 1 DMT Stroke Program Study with Hammersmith Medicines Research (UK)
Mar 01, 2021 7:00am EST Algernon Pharmaceuticals Appoints VP Research & Operations and Chief Medical Officer
Feb 25, 2021 7:00am EST Algernon Pharmaceuticals CEO to Speak at the Psychedelic Capital Virtual Investment Conference
